Posts Tagged ‘Chinese Investment’

Asian Citrus Holdings

We first squeezed a little Asian Citrus into our portfolio back in October 2009, taking up 254 shares in China’s largest orange plantation owner and operator at £4.27 a share. Before we had time to shake the tree a ten for one stock split was in the works which multiplied our holding by ten to 2,540 shares (and divided each shares worth by that very same multiple).

I like a stock split. I know splitting a stock is often nothing more than a venture in rhetoric but what it does do is produce news (although when a stock split is coupled with negative more business-defining developments it can have more devastating effects on price) and possibly put the company in the sights of a whole new body of investors. Anyway, I digress.

When a holding goes close to doubling in price within 12 months of getting on board, I’ll tend at least consider selling off half of that holding, so what’s left in the portfolio becomes a freebie in essence. It won’t stop me jumping back in if the timing’s right, but occasionally it’s nice to get some money in the bank, pat yourself on the back for a job well done and move your investment funds onto financial pastures new.

So in November of last year – rather serendipitously as Asian Citrus’ price near-peaked at 82 pence – we sold half of our holding (1,270 shares).

Today we still hold those 1,270 shares as Asian Citrus’ price continues its 2011 downtrend flirting with 60 pence as I type.

There was a failed acquisition in May of this year in which Asian Citrus would have acquired more than six square kilometres of Chinese citrus groves, and increased its tree numbers by one-third (more on that at AgriMoney).

This news, whilst probably expected by a lot of those in the know, could go some way to explaining the 25% drop in price since the peaks of late last year, but let’s be honest, AIM share prices across the board have pretty much sucked in 2011. At the end of the day, Asian Citrus has probably been one of the stalwarts of our portfolio this year.

But the news isn’t all bad. Today Asian Citrus announced:

its latest production volume of its Summer Orange crop at its Hepu Plantation was 73,194 tonnes compared with 72,408 tonnes for the harvest undertaken at the same time last year, representing an increase of 1.1%. The yield of the Summer crop is in line with management’s expectations for summer production.

The annual production volume for the Group increased from approximately 186,938 tonnes to about 216,892 tonnes in the current year which represents an increase of approximately 16.0%.

Interactive Investor in a Stock to Watch piece from March of this year, touched on a very important macro-economic factor that alone highlights the massive growth potential for Asian Citrus:

The demand for fresh fruit continue to enjoy support from China’s burgeoning middle class which has a taste for various Western lifestyle products. There appears to be a social trend towards drinking fresh orange juice and Asian Citrus has taken initiative by way of last October’s £165 million acquisition of Beihai BPG Food & Beverage, a producer of fruit juice concentrate. Management said the overall benefits to the group put it in a strong position for this “booming, though largely unexploited fruit juice market”.

There were also some very encouraging highlights from Februaury’s interim results. Notably that:

  • Revenue from the sale of oranges grew by approximately 36.6% to approximately RMB525.7m (1H 2009/10: RMB: 384.8 m)
  • Increased direct sales volumes to supermarkets up by approximately 21.9% to 38,572 tonnes (1H 2009/10: 31,632 tonnes). Renewed supply contracts with all existing supermarket customers

And this from Tony Tong, Chairman of Asian Citrus Holdings:

“The Group is progressing well and is increasing its presence in the Chinese retail market with higher production volume of direct sales to supermarkets. The completion of the acquisition of Beihai BPG is an important milestone for the Group in moving downstream and offers the Group better flexibility in dealing with the ever-changing needs of the consumer market. With the expected growth of the Chinese economy, we are confident that the demand for high quality oranges and juice concentrates in China will continue to grow, providing the Group with an exciting opportunity to further expand its business in both the agricultural and fruits processing businesses. The Group will continue to build on its existing market leading position by expanding its distribution network, increasing its production capacity and enhancing its sourcing capability through further development of its nursery business.”

So with 2.6 million fruit-producing trees doing their thing between their Hepu and Xinfeng Plantations and another 740,000 trees in the ground on their way to producing fruit, Asian Citrus remains a juicy hold for Investor Trader.

Sorry ’bout that, thanks again for dropping by.

Sale – Hutchison China Meditech

The first of our eight transactions for late December 2010 was the sale of another tranche of Hutchison China Meditech.

We bought in to HCM.L in July 2010, taking up 520 shares at £3.14 a share. We first took profit earlier in December selling 220 shares at £5.10 and then again with this more recent sale of 100 shares at £4.95.

Our original outlay (excluding dealer costs) was £1,632.80 and our two December sales have netted £1,122.00 and £495.00 respectively or £1,617.00 in total.

In effect we’ve re-couped our original investment and we still own 200 shares which are currently trading at five quid, valuing our holding at £1,000. Not bad for nowt.

Here’s the reasoning behind our orignal purchase and according to the bulletin boards and a handful of 2011 tipsters, the coming year could well provide more price increases for HCM.L. Here’s hoping.

So why sell now? I always feel comfortable after taking the initial investment from a holding, the rest is gravy. There’s no guarantees in investing so taking profit – even if in hindsight it’s a little premature – should always been done with at least a little smile. After all, that’s what this game is about.

It’s money in the bank and for the moment anyway, money I think I can get to perform better elsewhere. More on that soon.

Thanks again for dropping by and here’s to a profitable 2011 for all.

If you haven’t done so already pay a visit to Kiva – a £25 micro loan is a great way to give a hand to a third-world entrepreneurs looking to get a start in small business.

Sale – Hutchison China Meditech

With a handful of shares on my must-have before Christmas list we chopped the top off a few of our more profitable holdings last week.

This is never easy to do, especially when you know there’s more to come. I’m a big fan of letting the good ones run (unfortunately I’ve been known to let the bad ones run too – see Cosalt – though I’m assured there’s good news to come…). But sometimes the potential and the pull of undervalued or oversold shares elsewhere is just too strong to ignore.

First of our performing shares to contribute to my special socialist model of portfolio management was Hutchison China Meditech (HCM.L). A wonderfully performing Chinese chunk of AIM that had leapt in price from £3.14 when we jumped in back in July of this year to £5.10 when we sold 220 of them off on 12th November.

Here’s the reasoning behind our original purchase and nowt has changed.

We’re still holding 300 of these bad boys and we’re still expecting big things.

Sale – Renesola

With last rites being performed on Renesola’s AIM listing before shifting their focus solely to their New York Stock Exchange listing, last Thursday 4th November we sold off our final tranche of 500 shares of our portfolio stalwart for 4.0150 pence a share and a total return of £2,007.50 before dealer costs.

We were averaged into Renesola at £1.12 a share so we took a 350% profit on Renesola this time round. Renesola has always been good to me over the years. Taking me up toward the giddy heights of £7 before I lost my nerve and smacked the sell key and letting me slip back in under a quid in that very same year. A favourite of the shorters so there’s always been plenty of banter on the BBs to boot. It’s been a wonderful ride.

Since we set out on the Investor Trader journey back in April 2009, Renesola has been our most heavily traded share, having bought in and out on nine occasions in the past 18 months. She was our financial muse. We’ll be sad to see her go.

As a token of our respect we’ve splashed a little cash back into the solar market with PV Crystalox Solar and of course there’s still a Chinese connection in our portfolio with Asian Citrus Holdings Limited and Hutchison China Meditech which are both performing admirably.

But nothing can ever replace that special blend of an alternative energy AIM share from China, in my mind at least. They’re not tears on my keyboard, just sweat from this spicy Szechuan chicken.

Sale – A Little More Renesola

So we pulled the trigger on Renesola and sold off 500 shares – half our holding – last Wednesday at a price of £3.5375 per share. The reasoning: well, besides SOLA.L pushing some two year highs, we’re working to a little bit of a deadline  before Renesola dumps its AIM listing and takes all of its toys to New York.

So whilst it’s always nice to bank a triple-bagger (we are averaged into Renesola at £1.1227 per share) there’s still a sense of loss at what could have been. Put it this way. If Renesola’s move away from AIM wasn’t imminent, I wouldn’t have contemplated selling. Renesola’s chart of late is a ripper.

Now I know there are European based brokers out there willing and able to deal in New York and today markets are truly international, but to be honest, I’ve been happy in the past sticking primarily with UK based shares, albeit in this case with Chinese operations and a joint NYSE listing.

Adding a US component to my portfolio seems like an almost unnecessary risk. Close of markets in New York is past my bed time so there’s an element of not always being fully informed too. That’s my justification at any rate.

I’m still holding a further 500 shares and the price is still rising (it’s just touched £3.70 as I type) so I’ve still a got a few weeks left to decide whether to follow Renesola to the US.


The Day in Numbers





Our Charismatic Benefactors

Our Friends at Kiva

Investor Trader Categories

Investor Trader Archives

Disclaimer: Investor Trader is the blog of a single, personal investor. The owner of this blog is not a citizen of the United Kingdom nor is he based in the United Kingdom and the blog is not hosted in the United Kingdom. The owner has never received any form of compensation for providing investment recommendations and has never in the past been employed in any capacity where he has provided investment recommendations. Investor Trader does not make investment recommendations and no information displayed on its pages should be considered as investment advice. Nothing on Investor Trader should be interpreted as a recommendation or solicitation to buy or sell any securities or investments. All trades are first reported on Investor Trader at least a day or two after the fact (but more often a week or two), never live. Investor Trader is here to journal my attempts to make a few quid from the markets and possibly to entertain you a little into the bargain. Please, please, please, do your own piles of research and if you want good investment advice go out and find someone who does this sort of thing for a living (i.e. not me). Most of my investment decisions are based on gut feelings, hearsay, unfounded rumour and whether or not I like the cut of a company logo. You've been warned!
Copyright © 2011 Investor Trader
Market data by Yahoo Finance - all prices delayed by at least 15 minutes


TopOfBlogs Finance Finance blogs